Whitfield B. Growdon, MD

Articles by Whitfield B. Growdon, MD

Dr Growdon on the Withdrawal of Later-Line Indication For Olaparib in BRCA-Mutated Ovarian Cancer

July 28th 2023

Whitfield B. Growdon, MD, expands on the FDA’s decision to withdraw the later-line indication of olaparib for patients with BRCA-mutated ovarian cancer.

Latest Updated Articles

Trending on OncLive

Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial

Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia

QTX3034 Plus Cetuximab Receives FDA Fast Track Designation in KRAS G12D–Mutated CRC